Barclays
ALGS icon

Barclays’s Aligos Therapeutics ALGS Stock Holding History

Barclays’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$147 – 5213
2025
Q3 		$147 Buy
+15
New +$137 ﹤0.01% 5257
2022
Q3 		– Sell
-117
Closed -$4K – 4757
2022
Q2 		$4K Sell
117
-201
-63% -$6.83K ﹤0.01% 4808
2022
Q1 		$16K Buy
+318
New +$25.5K ﹤0.01% 4496

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Barclays's ALGS Position: Q4 2025 in Review

Barclays sold out of Aligos Therapeutics (ALGS) in Q4 2025, closing a stake of 15 shares — an estimated $147 sold.

Barclays first reported a position in ALGS in Q1 2022 and held it in 3 quarters. The position peaked at $16K in Q1 2022. 40 funds tracked by Wall St. Rank hold ALGS as of Q4 2025.

  • Barclays reported no remaining Aligos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 15 Aligos Therapeutics shares in Q4 2025, an estimated $147.
  • Barclays first reported a position in Aligos Therapeutics in Q1 2022 and held it in 3 quarters.
  • Barclays's Aligos Therapeutics position peaked at $16K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.